PFOS is a legacy PFAS compound that was once widely used in stain repellents, firefighting foams, and surface coatings, and its extreme chemical stability is precisely what makes it an environmental headache. The carbon-fluorine bonds that give PFOS its useful surfactant properties also render it nearly indestructible in natural systems, earning the broader class the nickname forever chemicals. Regulatory agencies have taken notice: the United States Environmental Protection Agency has moved to establish national primary drinking water regulations for PFAS, and the European Chemicals Agency has incorporated PFAS into its persistent, bioaccumulative and toxic assessment frameworks. Yet while the toxicity of PFOS has been extensively characterized in fish and other conventional laboratory models, sediment-dwelling invertebrates, the organisms that live in direct and prolonged contact with contaminated particles, have received far less attention. That gap matters, because benthic animals occupy a critical position in aquatic food webs and can serve as conduits for contaminant movement from sediments into higher trophic levels.

The research team, led by Xiangran Yin with Weitao Shen and Lan Fu as corresponding authors, designed a 14-day exposure experiment using a static sediment-water microcosm system. This setup allowed the leeches to experience PFOS in a context that approximates their natural habitat, with both a water column and a sediment phase present. Four exposure concentrations were tested, and the researchers measured three things over time: how much PFOS accumulated in leech tissues, how a panel of antioxidant-related biomarkers changed, and how antithrombin activity, a measure tied to the leech’s famous blood-anticoagulating biochemistry, responded. The choice of P. manillensis was deliberate. The species is listed in the Pharmacopoeia of the People’s Republic of China, is commercially cultured, and has well-characterized anticoagulant biochemistry, making it both ecologically relevant and practically tractable as a laboratory model.

To quantify accumulation dynamics, the team fitted their tissue concentration data to a dual-box kinetic model, estimating an absorption rate constant, K1, and a release rate constant, K2. The results were unambiguous. Across all exposure concentrations, K1 consistently exceeded K2, meaning that the rate at which leeches took up PFOS outpaced the rate at which they could eliminate it. Tissue burdens climbed steadily with exposure duration, and the effect was most pronounced at the highest exposure level. In practical terms, this suggests that during the exposure window the leeches never reached a steady state where uptake and elimination balanced out; they were still accumulating PFOS when the experiment ended. For a benthic organism in a chronically contaminated waterway, where exposure can continue for months or years, that kinetic imbalance points toward a substantial potential for long-term body burdens.

Why does PFOS accumulate so readily in animal tissues? The answer lies in its molecular behavior. Unlike many hydrophobic contaminants that partition into fat stores, PFOS binds strongly to proteins, particularly those with fatty acid binding domains. Studies in rainbow trout, carp, and zebrafish have shown that serum proteins and liver fatty acid binding proteins act as internal reservoirs for perfluorinated acids, and competitive partitioning among PFAS compounds of different chain lengths can further shape where these chemicals end up in the body. A leech, an animal whose whole biology revolves around blood and protein-rich secretions, may offer abundant protein binding sites for PFOS. The researchers’ finding that accumulation continued to rise throughout the exposure period is consistent with this protein-binding mechanism, which favors slow equilibration and slow clearance.

The biochemical side of the study focused on oxidative stress, a well-established response to many environmental toxicants. When organisms encounter reactive chemical stressors, they generate reactive oxygen species that can damage lipids, proteins, and DNA. Antioxidant enzymes such as superoxide dismutase form the first line of defense, converting superoxide radicals into less harmful species. In the exposed leeches, PFOS induced significant oxidative stress overall. Total superoxide dismutase activity followed a distinctive pattern: it initially decreased and then subsequently increased over the exposure period, a trajectory that may reflect an early phase of enzyme inhibition or depletion followed by a compensatory upregulation of antioxidant defenses. Total antioxidant capacity, which integrates the combined activity of the animal’s full antioxidant arsenal, displayed an inverted U-shaped temporal response, rising and then falling across the 14 days. These non-linear patterns underscore a key point in ecotoxicology: biomarker responses are dynamic, and single time-point measurements can miss the full arc of an organism’s physiological struggle.

Perhaps the most intriguing finding concerns antithrombin activity. Leeches are famous for their anticoagulant chemistry, most notably hirudin, a potent thrombin inhibitor that has been studied for applications ranging from cardiovascular protection to antifibrotic therapy. The researchers found that PFOS exposure produced significant temporal changes in antithrombin activity, and that this activity was significantly correlated with total protein content, total superoxide dismutase activity, and total antioxidant capacity. This statistical coupling suggests that the leech’s anticoagulant biochemistry does not operate in isolation from its stress responses; rather, contaminant pressure appears to ripple through interconnected biochemical networks linking oxidative defense, protein metabolism, and anticoagulation. Prior work on related leech species has shown that PFAS mixtures can perturb acute inflammatory responses, and peptidomic studies continue to uncover new anticoagulant peptides in P. manillensis, so the intersection of pollution and leech pharmacology is a frontier with real biomedical as well as ecological stakes.

The broader context of PFAS contamination in sediments gives these findings added weight. Surveys of surface sediments in China’s marginal seas have documented decade-long shifts in both legacy and emerging PFAS compounds, with evidence of ongoing production and persistent ecological risk. PFAS have been shown to migrate downward through lake sediment profiles, complicating historical trend reconstructions, and elevated PFAS levels have been measured in freshwater benthic macroinvertebrates in the Hudson River watershed. Bioturbation, the sediment-disturbing activity of burrowing and feeding organisms, has been demonstrated to affect PFAS uptake from sediments by both invertebrates and rooted plants. In other words, the sediment compartment is not a chemical sink where contamination goes to rest; it is an active zone of exchange, and the organisms living there are both exposed and consequential.

What the new study adds is a candidate biomonitoring tool tailored to that zone. Fish are mobile and can avoid contaminated patches; water sampling captures only the dissolved fraction at a moment in time. A benthic leech, by contrast, sits in continuous contact with sediment and integrates exposure over days to weeks. The authors present their results as preliminary evidence for the potential use of medicinal leeches as freshwater benthic biomonitoring organisms, and the combination of measurable accumulation kinetics, responsive antioxidant biomarkers, and a unique antithrombin endpoint gives the species a distinctive analytical profile. The dual-box model framework they applied could be extended to compare uptake and elimination across sites, concentrations, or co-occurring contaminants, providing a quantitative basis for field deployment.

Caveats remain, as the researchers themselves acknowledge. The 14-day exposure captures early accumulation dynamics but not the long-term steady state or the full elimination phase, and laboratory microcosms cannot reproduce every variable of a natural waterway, from seasonal temperature shifts to complex mixtures of pollutants. The correlations between antithrombin activity and other biochemical indicators are associations, not demonstrations of mechanism. Still, the study opens a genuinely novel window onto PFOS ecotoxicology. As regulators worldwide tighten PFAS limits and remediation efforts grapple with contaminated sediments, understanding how the organisms at the base of benthic food webs absorb and respond to these chemicals becomes essential. A leech that quietly records its chemical history in its tissues and its biochemistry may prove to be one of the most informative witnesses freshwater science has.

Subject of Research: PFOS bioaccumulation and biochemical toxicity responses in the freshwater benthic leech Poecilobdella manillensis

Article Title: Bioaccumulation and biochemical responses to perfluorooctane sulfonate (PFOS) exposure in the freshwater benthic leech (Poecilobdella manillensis)

Article References: Yin, X., Sun, Z., Wang, B., Chen, J., Guo, R., Shen, W., & Fu, L. (2026). Bioaccumulation and biochemical responses to perfluorooctane sulfonate (PFOS) exposure in the freshwater benthic leech (Poecilobdella manillensis). Environmental Monitoring and Assessment, 198(10), Article 1119. https://doi.org/10.1007/s10661-026-15944-4

Image Credits: AI Generated

DOI: 10.1007/s10661-026-15944-4

Keywords: PFOS, PFAS, leech, Poecilobdella manillensis, bioaccumulation, oxidative stress, antioxidant biomarkers, antithrombin activity, sediment, freshwater biomonitoring, ecotoxicology, toxicokinetics

Methylmercury is not an exotic industrial chemical but a routine contaminant of the aquatic food chain. Bacteria in sediments convert inorganic mercury, released by coal combustion and other human activities, into methylmercury, which then climbs the food web and concentrates in large predatory fish such as tuna, swordfish and shark. Because the compound crosses the placenta and the blood-brain barrier efficiently, a developing fetus can be exposed at levels higher than those measured in the mother’s blood. Regulatory agencies have long issued consumption advisories for pregnant people, but the doses used in laboratory toxicology have often been far higher than anything a person would encounter, making it difficult to translate animal findings into public health guidance. The new study was designed specifically to close that gap.

The researchers fed timed-pregnant Sprague-Dawley rats diets containing either a low dose of 400 parts per billion methylmercury or a high dose of 800 parts per billion, beginning on gestational day 8 and continuing through late gestation or parturition. These concentrations were chosen deliberately to mirror federal and state fish consumption advisory guidelines, meaning the animals were not receiving a toxicological hammer blow but something closer to what a person eating contaminated fish might experience. A control group received vehicle-treated diet. The team then measured mercury accumulation in maternal, placental, fetal and eventually pubertal tissues using direct thermal decomposition, gold amalgamation and atomic absorption spectrometry, a gold-standard analytical approach for total mercury quantification.

The first striking result concerns persistence. Mercury accumulated in a dose-dependent manner not only in the mothers and their placentas and fetuses, but also in the tissues of offspring examined at puberty, long after the exposure window had closed. This long-term retention demonstrates that even brief, environmentally realistic prenatal exposure leaves a measurable body burden that lingers through a substantial fraction of the animal’s life. Equally notable was the biodistribution: pubertal females carried more mercury in their brain, muscle and blood, whereas males accumulated more in the liver. Such sex-specific toxicokinetics had been underrecognized, and they suggest that the same exposure can seed different tissues with the toxicant depending on the sex of the offspring, potentially setting the stage for divergent downstream effects.

Developmental timing itself proved vulnerable. In the high-dose group, offspring showed delayed eye opening, a classic milestone of postnatal neurological maturation. More dramatically, pubertal onset was delayed in males but not in females, pointing to a sex-specific disruption of the neuroendocrine machinery that initiates reproductive maturation. Puberty is orchestrated by a finely tuned hypothalamic-pituitary-gonadal axis, and its timing is increasingly recognized as a sensitive indicator of developmental perturbation. A delay confined to one sex implies that the biological variables governing that axis, including hormonal milieu and possibly the differential tissue burdens of mercury, interact to shape vulnerability in ways that a single-sex study would entirely miss.

Growth trajectories also diverged by sex in ways that hint at lasting metabolic programming. Males exposed prenatally to the high dose of methylmercury weighed less during late adolescence, while their female counterparts weighed more. The placenta offered an early clue to these divergent paths: high-dose exposure reduced placental weight but increased placental efficiency, a measure of how effectively the organ supports fetal growth per unit of tissue. The concept of developmental programming holds that stressors during critical windows can permanently recalibrate metabolic setpoints, and the opposing adolescent weight patterns observed here are consistent with sex-specific recalibration of energy balance, body composition or endocrine regulation that only becomes visible long after the exposure itself.

Blood-based biomarkers measured at puberty deepened the picture of persistent internal disruption. The researchers used MILLIPLEX magnetic bead assays to profile plasma liver injury markers and a panel of cytokines and chemokines, and an advanced oxidation protein products assay to quantify circulating oxidized proteins. Markers of hepatic function, including arginase 1, sorbitol dehydrogenase, aspartate aminotransferase and 5-prime nucleotidase, were altered in patterns that depended on both sex and dose. Given that males preferentially sequestered mercury in the liver, the hepatic signal in that sex is particularly coherent with the toxicokinetic data, suggesting the organ bearing the greatest mercury burden also shows the clearest functional disturbance.

The inflammatory profile told a parallel story. Cytokines including tumor necrosis factor alpha, interleukin-2, interleukin-1 alpha, interleukin-17A and interleukin-6 were differentially altered by sex and methylmercury dose, indicating that prenatal exposure had imprinted a durable dysregulation on immune signaling that persisted into puberty. Chronic low-grade inflammation is a known contributor to a wide range of adult diseases, from cardiovascular disease to metabolic syndrome, and developmental immunology has increasingly emphasized that early-life exposures can set immune trajectories for life. The finding that a brief gestational exposure to a dietary contaminant can shift circulating inflammatory chemistry months later, and differently in each sex, underscores how far the consequences of prenatal toxicology can reach.

For public health, the implications are twofold. First, the doses used here were calibrated to real-world advisory levels rather than extreme laboratory exposures, which strengthens the argument that current guidance deserves continued scrutiny, particularly for populations that rely heavily on fish as a dietary staple. Fish remains an excellent source of protein and omega-3 fatty acids, and the study does not suggest that fish should be avoided altogether; rather, it reinforces the rationale behind advisories steering pregnant individuals toward low-mercury species. Second, and perhaps more broadly, the work is a forceful demonstration of why sex must be treated as a critical biological variable in developmental toxicology. Every endpoint the team examined, from mercury biodistribution to pubertal timing, growth and immune signaling, showed sex-dependent effects that a male-only or female-only design would have obscured or misrepresented.

The study, which was approved by the University of North Texas Health Science Center’s Institutional Animal Care and Use Committee and funded in part by the National Institutes of Health, arrives at a moment when regulatory science is actively wrestling with how to incorporate sex as a biological variable into risk assessment. As the authors conclude, environmentally relevant prenatal methylmercury exposure disrupts developmental trajectories and induces long-lasting, sex-specific alterations in growth, hepatic function and inflammatory signaling. Translating that conclusion from rats to humans will require further work, but the core lesson travels well: the developing fetus is exquisitely sensitive to its chemical environment, the effects of that environment may not declare themselves until adolescence, and assuming that males and females respond identically is no longer a defensible default in environmental health research.

Subject of Research: Sex-specific developmental toxicity of prenatal methylmercury exposure in rats

Article Title: Prenatal methylmercury exposure disrupts developmental trajectories and induces sex-specific toxicity in pubertal rats

Article References: Bradshaw, J. L., Wilson, E. N., Mabry, S., Gardner, J. J., Grief, A., Soulen, B. K., Ortega-Rodriguez, C. L., Armstrong, T. D., Lund, A. K., Roberts, A. P., & Cunningham, R. L. (2026). Prenatal methylmercury exposure disrupts developmental trajectories and induces sex-specific toxicity in pubertal rats. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00987-6

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00987-6

Keywords: methylmercury, prenatal exposure, developmental toxicology, sex differences, puberty, placental efficiency, hepatic biomarkers, inflammation, toxicokinetics, developmental programming, public health, rats

The review, conducted by researchers at the Universidade Federal do Rio Grande do Sul in Brazil, searched PubMed/Medline, Scielo and Google Scholar for articles and technical notes published between 2020 and 2024. From an initial pool of 108 works, 41 studies were included in the final analysis. The authors note that the United Nations Office on Drugs and Crime had recorded more than 120 opioid receptor agonists by 2024, divided into five subgroups: fentanyl analogues, U-series substances, nitazenes, piperazines and a miscellaneous category. Nitazenes stand out within this crowded field because of the sheer affinity of some analogues for the µ-opioid receptor. The first fatal case involving isotonitazene, one of the most notorious members of the family, was reported in the United States in August 2019, only months after the compound first appeared on the recreational market. Since then, metonitazene, butonitazene, flunitazene, etodesnitazene, protonitazene and N-pyrrolidinoetonitazene have all been identified in forensic casework, and between 2019 and 2025 a total of 32 nitazene analogues were reported by 36 countries.

What makes the current wave of nitazene activity particularly hazardous is the way these substances reach consumers. They are rarely sold as standalone products. Instead, they are frequently detected as adulterants in heroin, benzodiazepines, synthetic cannabinoids and even cocaine, often without the knowledge of the people who buy them. This adulteration broadens the population at risk far beyond habitual opioid users. In Brazil, a country where opioid misuse had historically been considered statistically insignificant, the arrival of nitazenes came through an unexpected channel: herbal smoking blends sold as synthetic cannabinoids. An analysis of 140 opioid samples seized by São Paulo state police over roughly one year found that 95 percent contained nitazene analogues, with metonitazene present in 72 percent of the nitazene-positive samples. In most of these cases the compounds appeared in combination with other drugs, meaning users were inhaling a potent opioid hidden inside a product they believed contained something else entirely.

The chemistry behind this potency is instructive. Nitazene analogues share a benzimidazole nucleus linked to an amine group, and small modifications to the side chains produce compounds with markedly different pharmacological profiles. Etonitazene, first synthesized in 1957, proved in animal models to be between 100 and 1000 times more potent than morphine, making it the most powerful compound of the 2-benzylbenzimidazole subclass. Isotonitazene ranked second in potency, followed by protonitazene, metonitazene and butonitazene. The electron-withdrawing nitro group at the 5-position of the ring, the structural feature that gives the nitazenes their name, reduces the basicity of the heteroaromatic ring and appears central to receptor binding. The basic properties of these molecules generally dominate over their acidic ones, owing to two basic moieties: the benzimidazole ring and a tertiary amine in the side chain. These subtle structural differences translate into dramatic differences in how strongly each compound activates opioid receptors and how long it stays bound to them.

Once inside the body, nitazene analogues follow a metabolic route that creates its own set of problems. Biotransformation is mediated primarily by cytochrome P450 enzymes in the liver, particularly the CYP2D6, CYP2B6 and CYP2C8 isoforms. Phase I metabolism oxidizes the parent compounds, introducing reactive and polar functional groups, while phase II conjugation adds glucuronides and sulfates to facilitate urinary excretion. Crucially, some of the metabolites generated along the way are pharmacologically active in their own right. The main urinary metabolite of isotonitazene, N-desethyl-isotonitazene, is actually more potent than the parent drug and has itself appeared for sale on the drug market. Metabolite profiling shows that the O-desalkyl metabolites of isotonitazene and metonitazene are the same molecule, complicating the interpretation of toxicological results, and in silico analysis of etazene suggests it is three times more lipophilic than morphine, crosses the blood-brain barrier readily and inhibits several major CYP enzymes. Genetic variation in CYP450 activity means metabolism can differ substantially between individuals, adding further unpredictability to overdose risk.

Clinically, nitazene exposure produces the effects expected of powerful opioids: euphoria, pain relief and relaxation, followed by drowsiness, dizziness, nausea, constipation and dry mouth. The life-threatening effect is respiratory depression, which can progress to cardiac arrest. Prolonged exposure leads to tolerance, dependence and a characteristic withdrawal syndrome that begins with anxiety, drug craving and lacrimation before escalating to tremors, muscle pain, tachycardia, hypertension and gastrointestinal distress. What distinguishes nitazenes from earlier opioid threats is the difficulty of reversing their overdoses with naloxone, the standard opioid antidote. Laboratory work suggests that nitazenes and fentanyl analogues dissociate slowly from the µ-opioid receptor, reducing naloxone sensitivity. A systematic review found that nitazene overdoses typically required naloxone doses in the range of 1 to 6 milligrams, compared with the 0.4 to 0.8 milligrams usually sufficient for heroin. In one Brazilian clinical case involving N-pyrrolidinoprotonitazene, a patient with a blood concentration of 3.0 nanograms per milliliter required three ampoules of naloxone, equivalent to 1.2 milligrams, before respiratory function improved. The short half-life of naloxone relative to these synthetic opioids also means respiratory depression can relapse, demanding repeated dosing and sustained monitoring.

Detecting nitazenes in biological samples presents a formidable analytical challenge. Because these compounds are so potent, they are consumed at microgram doses and clear the body rapidly, so timely sampling and highly sensitive instruments are essential. Liquid chromatography coupled with tandem mass spectrometry has become the method of choice, typically using whole blood as the primary matrix and liquid-liquid extraction for sample preparation. Related techniques, including GC-MS and LC-QTOF-MS, allow detailed chemical differentiation between analogues. Forensic scientists emphasize that robust documentation of exposure requires detecting the parent compound alongside N-desethyl, O-desalkyl and N-desethyl-O-desalkyl biomarkers, since metabolites are often more abundant than the original drug. Adding to the confusion, illicit production by the original synthetic route can generate positional isomer impurities that confound analytical interpretation. The review also highlights a promising harm-reduction tool: nitazene test strips, a lateral flow immunoassay commercially available since early 2024 and calibrated against isotonitazene. However, a Belgian laboratory evaluation found the strips failed to detect two analogues, metodesnitazene and etodesnitazene, even at high concentrations, underscoring how quickly the market evolves beyond the tools designed to monitor it.

The regulatory response has been uneven. Brazil formally controlled metonitazene in 2023 and has since listed ten more analogues, while its national rapid alert system for new psychoactive substances was only permanently formalized in early 2025. In a potentially significant shift, China introduced generic control of the entire nitazene structure in June 2025, meaning any new analogue containing the core scaffold is now illegal. The downstream effects on the illicit market remain uncertain, but similar generic controls on fentanyl precursors have previously reshaped supply chains in unpredictable ways. The review’s authors stress that underreporting remains a major obstacle to understanding the true scale of the problem, since many poisonings go unidentified without specialized testing and standardized reporting protocols are still lacking.

The core message from the toxicologists is that health systems must adapt before the crisis deepens. The combination of extreme potency, active metabolites, polysubstance adulteration and naloxone resistance creates a clinical scenario for which many emergency services are not adequately prepared. The authors call for specific intervention protocols, training for health professionals on the risks of synthetic opioids, and urgent advances in toxicokinetic and toxicodynamic research to support detection, treatment and rehabilitation programs. Without that foundation, they warn, public health authorities will continue to underestimate both the prevalence and the lethality of these compounds. As nitazene analogues spread through adulterated drug supplies worldwide, the gap between what users think they are consuming and what is actually in the sample may prove to be the deadliest variable of all.

Subject of Research: Toxicology of emerging nitazene analogue synthetic opioids and their overdose risks

Article Title: Toxicological aspects of emerging nitazene analogues as a new threat to the synthetic drug landscape

Article References: Martins, J. N., dos Santos, B. P., & Arbo, M. D. (2026). Toxicological aspects of emerging nitazene analogues as a new threat to the synthetic drug landscape. Discover Toxicology, 3(1), Article 5. https://doi.org/10.1007/s44339-026-00050-4

Image Credits: AI Generated

DOI: 10.1007/s44339-026-00050-4

Keywords: nitazenes, synthetic opioids, isotonitazene, metonitazene, fentanyl, naloxone, overdose, new psychoactive substances, toxicokinetics, respiratory depression, forensic toxicology, drug detection